TORONTO, Nov 8 (Reuters) - Neurochem said on Thursday it planned to ramp up development of its key Alzheimer’s disease treatment NRM-8499 and terminate European trials of its tramiprosate Alzheimer’s treatment as it shifts its focus on the fight with the disease.
